CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Gam-COVID-Vac LyoWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1086 Hydroxychloroquine Wiki 0.10
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D012141 Respiratory Tract Infections NIH 0.21
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0011947 Respiratory tract infection HPO 0.21

There is one clinical trial.

Clinical Trials


1 An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac Lyo" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers

the purpose of this study: to evaluate the safety, tolerability and immunogenicity of the drug "Gam-COVID-Vac Lyo", a lyofilizate for preparing solution for intramuscular administration, at various times after vaccination in healthy adult volunteers.

NCT04437875 Preventive Immunization COVID-19 Biological: Gam-COVID-Vac Lyo

Primary Outcomes

Description: Determination of antibody levels against the SARS-CoV-2 glycoprotein S measured by an ELISA vs. baseline values

Measure: The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days

Time: at days 0, 14, 21, 28, 42

Description: Determination of Number of Participants With Adverse Events

Measure: Number of Participants With Adverse Events

Time: through the whole study, an average of 180 days

Secondary Outcomes

Description: Determination of virus neutralizing antibody titer

Measure: The changing of virus neutralizing antibody titer

Time: at days 0, 14, 28, 42

Description: Determination of antigen-specific cellular immunity (specific T-cell immunity, in particular, IFN-gamma production or lymphoproliferation)

Measure: The changing of antigen-specific cellular immunity level

Time: at days 0, 14, 28


No related HPO nodes (Using clinical trials)